Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future

被引:429
作者
Ingelman-Sundberg, M [1 ]
机构
[1] Karolinska Inst, IMM, Div Mol Toxicol, SE-17177 Stockholm, Sweden
关键词
D O I
10.1016/j.tips.2004.02.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The field of cytochrome P450 pharmacogenetics has progressed rapidly during the past 25 years. All the major human drug-metabolizing P450 enzymes have been identified and cloned, and the major gene variants that cause inter-individual variability in drug response and are related to adverse drug reactions have been identified. This information now provides the basis for the use of predictive pharmacogenetics to yield drug therapies that are more efficient and safer. Today, we understand which drugs warrant dosing based on pharmacogenetics to improve drug treatment. It is anticipated that, in the future, genotyping could be used to personalize drug treatment for vast numbers of subjects, decreasing the cost of drug treatment and increasing the efficacy of drugs and health in general. I estimate that such personalized P450 gene-based treatment would be relevant for 10-20% of all drug therapy.
引用
收藏
页码:193 / 200
页数:8
相关论文
共 83 条
[1]   GENETIC-BASIS FOR DIFFERENCES IN DEBRISOQUIN POLYMORPHISM BETWEEN A SPANISH AND OTHER WHITE-POPULATIONS [J].
AGUNDEZ, JAG ;
MARTINEZ, C ;
LEDESMA, MC ;
LADONA, MG ;
LADERO, JM ;
BENITEZ, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (04) :412-417
[2]   Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden [J].
Aklillu, E ;
Herrlin, K ;
Gustafsson, LL ;
Bertilsson, L ;
Ingelman-Sundberg, M .
PHARMACOGENETICS, 2002, 12 (05) :375-383
[3]  
Aklillu E, 1996, J PHARMACOL EXP THER, V278, P441
[4]   STEADY-STATE PLASMA LEVELS OF NORTRIPTYLINE INTWINS - INFLUENCE OF GENETIC FACTORS AND DRUG THERAPY [J].
ALEXANDERSON, B ;
EVANS, DAP ;
SJOQVIST, F .
BMJ-BRITISH MEDICAL JOURNAL, 1969, 4 (5686) :764-+
[5]   Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status [J].
Barclay, ML ;
Sawyers, SM ;
Begg, EJ ;
Zhang, M ;
Roberts, RL ;
Kennedy, MA ;
Elliott, JM .
PHARMACOGENETICS, 2003, 13 (10) :627-632
[6]   MOLECULAR-BASIS FOR RATIONAL MEGAPRESCRIBING IN ULTRARAPID HYDROXYLATORS OF DEBRISOQUINE [J].
BERTILSSON, L ;
DAHL, ML ;
SJOQVIST, F ;
ABERGWISTEDT, A ;
HUMBLE, M ;
JOHANSSON, I ;
LUNDQVIST, E ;
INGELMANSUNDBERG, M .
LANCET, 1993, 341 (8836) :63-63
[7]   Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions [J].
Bertz, RJ ;
Granneman, GR .
CLINICAL PHARMACOKINETICS, 1997, 32 (03) :210-258
[8]   The relevance of alternative RNA splicing to pharmacogenomics [J].
Bracco, L ;
Kearsey, J .
TRENDS IN BIOTECHNOLOGY, 2003, 21 (08) :346-353
[9]   Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness [J].
Chou, WH ;
Yan, FX ;
de Leon, J ;
Barnhill, J ;
Rogers, T ;
Cronin, M ;
Pho, M ;
Xiao, V ;
Ryder, TB ;
Liu, WW ;
Teiling, C ;
Wedlund, PJ .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (02) :246-251
[10]   The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase [J].
Crespi, CL ;
Miller, VP .
PHARMACOGENETICS, 1997, 7 (03) :203-210